2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Conditions
Precancerous Conditions
214
Lymphoma
47
Leukemia
46
Multiple Myeloma
44
Leukemia, Lymphocytic, Chronic, B-Cell
42
Neoplasms, Plasma Cell
40
Precursor Cell Lymphoblastic Leukemia-Lymphoma
39
Monoclonal Gammopathy of Undetermined Significance
39
Lymphoma, Non-Hodgkin
38
Lymphoma, Mantle-Cell
37
Lymphoma, Large-Cell, Immunoblastic
37
Lymphoma, Large B-Cell, Diffuse
37
Lymphoma, Follicular
37
Myelodysplastic Syndromes
36
Burkitt Lymphoma
36
Lymphoma, B-Cell, Marginal Zone
35
Leukemia, Myeloid, Acute
35
Hodgkin Disease
35
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
34
Myeloproliferative Disorders
34
Immunoglobulin Light-chain Amyloidosis
33
Waldenstrom Macroglobulinemia
32
Immunoblastic Lymphadenopathy
32
Uterine Cervical Neoplasms
31
Lymphoma, Large-Cell, Anaplastic
31
Primary Myelofibrosis
30
Thrombocythemia, Essential
29
Leukemia, Hairy Cell
29
Leukemia, Biphenotypic, Acute
29
Uterine Cervical Dysplasia
28
Interventions
Psychotherapy
1
Psilocybin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hospice
×
Other neoplasm
×
Clear all
NCT04950608
2026-02-17
PATH
Dana-Farber Cancer Institute
Phase 2
Completed
15 enrolled
26 charts